TNG 462
Alternative Names: TNG-462Latest Information Update: 21 Mar 2024
At a glance
- Originator Tango Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
- Preclinical Cancer
Most Recent Events
- 31 Dec 2023 TNG 462 receives Orphan Drug status for Soft tissue sarcoma in USA
- 26 May 2023 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France, Spain (PO) (NCT05732831)
- 26 May 2023 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT05732831)